Squarepoint Ops LLC Buys New Position in Anavex Life Sciences Corp. (NASDAQ:AVXL)

Squarepoint Ops LLC purchased a new position in Anavex Life Sciences Corp. (NASDAQ:AVXL) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund purchased 45,352 shares of the biotechnology company’s stock, valued at approximately $191,000. Squarepoint Ops LLC owned 0.05% of Anavex Life Sciences as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Jupiter Asset Management Ltd. increased its position in Anavex Life Sciences by 675.0% during the first quarter. Jupiter Asset Management Ltd. now owns 804,642 shares of the biotechnology company’s stock worth $4,096,000 after acquiring an additional 700,812 shares during the period. Renaissance Technologies LLC grew its position in Anavex Life Sciences by 483.8% in the 2nd quarter. Renaissance Technologies LLC now owns 466,437 shares of the biotechnology company’s stock worth $1,968,000 after purchasing an additional 386,537 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Anavex Life Sciences by 1.2% during the 1st quarter. Vanguard Group Inc. now owns 4,414,682 shares of the biotechnology company’s stock worth $22,471,000 after purchasing an additional 54,034 shares during the period. Bank of New York Mellon Corp raised its position in shares of Anavex Life Sciences by 17.1% during the second quarter. Bank of New York Mellon Corp now owns 280,556 shares of the biotechnology company’s stock valued at $1,184,000 after buying an additional 40,895 shares during the last quarter. Finally, Marshall Wace LLP bought a new stake in shares of Anavex Life Sciences in the second quarter valued at about $166,000. 31.55% of the stock is currently owned by institutional investors and hedge funds.

Anavex Life Sciences Price Performance

AVXL opened at $5.38 on Monday. Anavex Life Sciences Corp. has a fifty-two week low of $3.25 and a fifty-two week high of $10.45. The firm’s fifty day moving average price is $5.77 and its two-hundred day moving average price is $4.93. The company has a market capitalization of $455.37 million, a P/E ratio of -10.76 and a beta of 0.61.

Anavex Life Sciences (NASDAQ:AVXL) last posted its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01. During the same quarter last year, the company posted ($0.14) EPS. On average, equities research analysts expect that Anavex Life Sciences Corp. will post -0.55 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have commented on AVXL shares. EF Hutton Acquisition Co. I raised Anavex Life Sciences to a “strong-buy” rating in a report on Monday, July 22nd. HC Wainwright restated a “buy” rating and issued a $40.00 target price on shares of Anavex Life Sciences in a research note on Thursday, August 1st.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.